This website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our Privacy Policy. I Accept About Science Partnerships News Careers Contact Mobilizing the Human Immune System to Combat Disease HiFiBiO Therapeutics is an emerging multinational company that will soon transform patient care. LATEST NEWS NOV 1, 2021 HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301 HFB200301 is a First-In-Class TNFR2 Agonist Antibody for the treatment of DIS™ Defined Solid Tumors CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, and PARIS – November 1, 2021 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for … SEP 23, 2021 HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, PARIS – September 23, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and single-cell science, today announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance that was established to accelerate discovery, optimization, and delivery of … AUG 9, 2021 HiFiBiO Strengthens its Senior Leadership Team in Preparation for First-in-Human Studies of Two Lead Immunoncology Programs and a Sustainable Pipeline (From left to right) Christos Hatzis, PhD, Vice President, Head of Clinical Pharmacogenomics, John Pallante, Vice President, Head of Clinical Operations, and Edward Rocnik, PhD, Executive Director, Head of CMC have joined the company’s senior leadership team. CAMBRIDGE, Mass. – August 9, 2021 – HiFiBiO Therapeutics has onboarded three new senior leaders to help drive … See all news Unprecedented Discovery and Development Engine Drug Discovery and Development Expertise Transformational Single-Cell Platform Dynamic and Sustainable Pipeline Unique Immune Profiling Translational Focus Open-Innovation Strategy Our Multinational Presence Join Our Team Learn More Americas Europe Asia About Science Partnerships News Careers Contact © HiFiBiO Therapeutics, 2021. All Rights Reserved. Privacy Policy Manage cookie settings